Table 3.
Antitumor Activity of Vidutolimod and Atezolizumab With and Without RT
| Antitumor Activity Measure | Part A Vidutolimod + Atezolizumab n = 13 |
Part B Vidutolimod + Atezolizumab + RT n = 16 |
|---|---|---|
| Best ORR by RECIST v1.1, INV-assessed, % (95% CI) | 0 (0–24.7) | 0 (0–20.6) |
| CR, n (%) | 0 | 0 |
| PR, n (%) | 0 | 0 |
| Stable disease, n (%) | 3 (23.1) | 8 (50.0) |
| PD, n (%) | 8 (61.5) | 5 (31.3) |
| NE,a n (%) | 2 (15.4) | 3 (18.8) |
| Median PFS INV-assessed, mo (95% CI) | 1.8 (1.1–2.9) | 1.7 (1.3–2.2) |
CI, confidence interval; CR, complete response; INV, investigator; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST v1.1, Response Evaluation in Solid Tumors, version 1.1; RT, radiation therapy.
a
Two patients in part A and two patients in part B discontinued before follow-up imaging was performed; one patient in part B had incomplete postbaseline imaging.